The Absorption of Supplemental Magnesium Oxide Compared to Magnesium Citrate in Healthy Subjects With no Apparent Heart Disease View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2010-2011

ABSTRACT

The magnesium food content in the Western world is consistently reducing. Hypomagnesemia is common in hospitalized patients, especially in the elderly with coronary artery disease (CAD) and/or those with chronic heart failure. Hypomagnesemia is associated with increased incidence of diabetes mellitus, metabolic syndrome, mortality rate from coronary artery disease (CAD) and all cause. Magnesium supplementation improves myocardial metabolism, inhibits calcium accumulation and myocardial cell death; it improves vascular tone, peripheral vascular resistance, afterload and cardiac output, reduces cardiac arrhythmias and improves lipid metabolism. Magnesium also reduces vulnerability to oxygen-derived free radicals, improves human endothelial function and inhibits platelet function, including platelet aggregation and adhesion. The data regarding the absorption difference between supplemental magnesium oxide and magnesium citrate in humans is spare. Detailed Description Two oral preparations of magnesium are available in Israel: 1. Magnesium Diasporal (magnesium citrate, elemental magnesium 98.6 mg), PROTINA GMBH, ISMANING, Germany 2. Magnox 520 TM (magnesium oxide, 520 mg elemental magnesium), Naveh Pharma Ltd., Israel. The data regarding the absorption difference between the two supplemental magnesium preparations (magnesium oxide and magnesium citrate) in humans is spare. Primary objective: To find out the absorption of magnesium citrate compared to magnesium oxide in healthy subjects with no apparent heart disease. More... »

URL

https://clinicaltrials.gov/show/NCT00994006

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The magnesium food content in the Western world is consistently reducing. Hypomagnesemia is common in hospitalized patients, especially in the elderly with coronary artery disease (CAD) and/or those with chronic heart failure. Hypomagnesemia is associated with increased incidence of diabetes mellitus, metabolic syndrome, mortality rate from coronary artery disease (CAD) and all cause. Magnesium supplementation improves myocardial metabolism, inhibits calcium accumulation and myocardial cell death; it improves vascular tone, peripheral vascular resistance, afterload and cardiac output, reduces cardiac arrhythmias and improves lipid metabolism. Magnesium also reduces vulnerability to oxygen-derived free radicals, improves human endothelial function and inhibits platelet function, including platelet aggregation and adhesion. The data regarding the absorption difference between supplemental magnesium oxide and magnesium citrate in humans is spare.\n\nDetailed Description\nTwo oral preparations of magnesium are available in Israel: 1. Magnesium Diasporal (magnesium citrate, elemental magnesium 98.6 mg), PROTINA GMBH, ISMANING, Germany 2. Magnox 520 TM (magnesium oxide, 520 mg elemental magnesium), Naveh Pharma Ltd., Israel. The data regarding the absorption difference between the two supplemental magnesium preparations (magnesium oxide and magnesium citrate) in humans is spare. Primary objective: To find out the absorption of magnesium citrate compared to magnesium oxide in healthy subjects with no apparent heart disease.", 
    "endDate": "2011-03-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00994006", 
    "keywords": [
      "magnesium oxide", 
      "magnesium", 
      "healthy subject", 
      "Western world", 
      "hospitalized patient", 
      "coronary artery disease", 
      "chronic heart failure", 
      "increased incidence", 
      "diabetes mellitus", 
      "metabolic syndrome", 
      "mortality", 
      "supplementation", 
      "myocardial metabolism", 
      "calcium accumulation", 
      "myocardial cell", 
      "vascular tone", 
      "peripheral vascular resistance", 
      "afterload", 
      "cardiac output", 
      "Cardiac Arrhythmia", 
      "lipid metabolism", 
      "vulnerability", 
      "oxygen-derived free radical", 
      "endothelial function", 
      "platelet function", 
      "platelet aggregation", 
      "adhesion", 
      "absorption", 
      "human", 
      "preparation", 
      "Israel", 
      "TM", 
      "pharma", 
      "primary objective", 
      "heart disease"
    ], 
    "name": "The Absorption of Supplemental Magnesium Oxide Compared to Magnesium Citrate in Healthy Subjects With no Apparent Heart Disease", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00994006"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00007.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.413795.d", 
        "type": "Organization"
      }
    ], 
    "startDate": "2010-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1684/mrh.2012.0305", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007887697", 
          "https://doi.org/10.1684/mrh.2012.0305"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1684/mrh.2010.0202", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078139275"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00994006"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00994006'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00994006'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00994006'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00994006'


 

This table displays all metadata directly associated to this object as RDF triples.

61 TRIPLES      16 PREDICATES      52 URIs      44 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00994006 schema:about anzsrc-for:3048
2 schema:description The magnesium food content in the Western world is consistently reducing. Hypomagnesemia is common in hospitalized patients, especially in the elderly with coronary artery disease (CAD) and/or those with chronic heart failure. Hypomagnesemia is associated with increased incidence of diabetes mellitus, metabolic syndrome, mortality rate from coronary artery disease (CAD) and all cause. Magnesium supplementation improves myocardial metabolism, inhibits calcium accumulation and myocardial cell death; it improves vascular tone, peripheral vascular resistance, afterload and cardiac output, reduces cardiac arrhythmias and improves lipid metabolism. Magnesium also reduces vulnerability to oxygen-derived free radicals, improves human endothelial function and inhibits platelet function, including platelet aggregation and adhesion. The data regarding the absorption difference between supplemental magnesium oxide and magnesium citrate in humans is spare. Detailed Description Two oral preparations of magnesium are available in Israel: 1. Magnesium Diasporal (magnesium citrate, elemental magnesium 98.6 mg), PROTINA GMBH, ISMANING, Germany 2. Magnox 520 TM (magnesium oxide, 520 mg elemental magnesium), Naveh Pharma Ltd., Israel. The data regarding the absorption difference between the two supplemental magnesium preparations (magnesium oxide and magnesium citrate) in humans is spare. Primary objective: To find out the absorption of magnesium citrate compared to magnesium oxide in healthy subjects with no apparent heart disease.
3 schema:endDate 2011-03-01T00:00:00Z
4 schema:keywords Cardiac Arrhythmia
5 Israel
6 TM
7 Western world
8 absorption
9 adhesion
10 afterload
11 calcium accumulation
12 cardiac output
13 chronic heart failure
14 coronary artery disease
15 diabetes mellitus
16 endothelial function
17 healthy subject
18 heart disease
19 hospitalized patient
20 human
21 increased incidence
22 lipid metabolism
23 magnesium
24 magnesium oxide
25 metabolic syndrome
26 mortality
27 myocardial cell
28 myocardial metabolism
29 oxygen-derived free radical
30 peripheral vascular resistance
31 pharma
32 platelet aggregation
33 platelet function
34 preparation
35 primary objective
36 supplementation
37 vascular tone
38 vulnerability
39 schema:name The Absorption of Supplemental Magnesium Oxide Compared to Magnesium Citrate in Healthy Subjects With no Apparent Heart Disease
40 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00994006
41 schema:sdDatePublished 2019-03-07T15:23
42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
43 schema:sdPublisher Nde89e13c680b463195ccaca9a132838f
44 schema:sponsor https://www.grid.ac/institutes/grid.413795.d
45 schema:startDate 2010-01-01T00:00:00Z
46 schema:subjectOf sg:pub.10.1684/mrh.2012.0305
47 https://doi.org/10.1684/mrh.2010.0202
48 schema:url https://clinicaltrials.gov/show/NCT00994006
49 sgo:license sg:explorer/license/
50 sgo:sdDataset clinical_trials
51 rdf:type schema:MedicalStudy
52 Nde89e13c680b463195ccaca9a132838f schema:name Springer Nature - SN SciGraph project
53 rdf:type schema:Organization
54 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
55 rdf:type schema:DefinedTerm
56 sg:pub.10.1684/mrh.2012.0305 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007887697
57 https://doi.org/10.1684/mrh.2012.0305
58 rdf:type schema:CreativeWork
59 https://doi.org/10.1684/mrh.2010.0202 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078139275
60 rdf:type schema:CreativeWork
61 https://www.grid.ac/institutes/grid.413795.d schema:Organization
 




Preview window. Press ESC to close (or click here)


...